

8. Referências

Asthana et al. **Poly (amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acid anti-inflammatory active ingredient.** *AAPS pharmscitech*. 6(3) Article 67.2005.

Banu et al. **Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens?** *Molecular microbiol*, 44(1), (pp. 9-19). Blackwell Science Ltd.2002.

Barrell, B. G.. **Analysis of the Genome of Mycobacterium tuberculosis H37Rv.** Genetics and Tuberculosis: Novartis Foundation Symposium 217 (eds D. J. Chadwick and G. Cardew), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470846526.ch12.2008.

Becker et al. **Computational Biochemistry and Biophysics.** *Marcel Dekker, Inc*, 2001.512p.2001.

Berendsen et al. **Intermolecular Forces. Interaction models for water in reaction to protein hydration, in Intermolecular Forces.** Ed.B.Pullman, *Reidel*, (pp. 331-342) Dordrecht.1981.

Berendsen et al. **Molecular dynamics with coupling to an external bath.** *The Journal of Chemical Physics*, 81. 3684.1984.

Bhalgat et al. **Effect of chemical modification strategy on the characteristics of copper-67-labeled immuno-conjugates. Part II: Aggregation.** *Drug delivery*, V. 4. 3-7.1997.

Bhalgat et al. **Effect of chemical modification strategy on the characteristics of copper-67-labeled immuno-conjugates. Part I: Immunoreactivity.** *Drug Delivery*, v.4. 1-12.1997.

Brobeck. **Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide.** *Journal of controlled release*, (102)1.23-38.2004.

Buckley et al. **Characteristics and rifampicin sustained release.** *International dendrimers Symposium*, 59. 2007.

Canetta et al. **Scaling properties in the internal structure of dendrimer systems.** *Physica*, V.334. 235-243.2002.

Canetta, & Maimo. **Molecular dynamic analysis of the structure of dendrimers. beam interactions with materials and atoms.** *5th Topical Meeting*

on *Industrial Radiation and Radioisotope Measurement Applications*. Elsevier. 71-74.2003.

Carvalho et al. **Diagnóstico de resistência do mycobacterium tuberculosis à rifampicina utilizando-se da reação em cadeia da polimerase**. *Revista brasileira de ciências farmacêuticas*.v.43. 2007.

Chauhan et al. **Solubility Enhancement of indomethacin with poly (amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats**. *Journal of drug targeting* ,12. 575-583.2004

Chen et al. **Interactions between edndrimer biocides and bacterial membranes**. *Biomaterials*.v.23. 3359-3368.2002

Cheng et al. **The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs**. *European Journal of Medicinal Chemistry* ,V.43. 2291-2297.2008

Coura, J. R. **Dinâmica das doenças infecciosas e parasitárias**. Rio de Janeiro. Guanabara Koogan.990p.2003.

Cox & David. **Princípios de Bioquímica de Lehninger**. artmed.1269p.2011.

Cramer. **Essentials of computational chemistry theories and models**. *Wiley & Sons*. 607p. 2004.

Dalcomo et al. **Tuberculose multirresistente no Brasil: Histórico e medidas de controle**. *Rev Saúde Pública*,V.41 34-42.2007.

Ding et al. **pH-Responsive Drug Delivery Systems Based on Clickable Poly(L-glutamic acid)-Grafted Comb Copolymers**. *Macromolecular Research*.v20 292-301.2012.

Domenech. **Mycobacterium tuberculosis in the post genome age**. *Curr Opin Microbiol* ,(4)1 28-34. 2001

Drobniewski. **Is death inevitable with multiresistant TBplus HIVinfection?**. *Lnacet*,v349. 71-72.1997.

DRUG BANK. **DRUG BANK**. Retrieved 2012, from DRUG BANK: <http://www.drugbank.ca/>.2012.

Emanuele, M. N. **Crossing cellular barriers using dendrimer nanotechnologies**. *Anti-infectives/New Technologies*.v6. 522-527.2006.

Emmanuele. **Dendrimer-drug interactions**. *Advanced drug delivery*.(57)15 2147-2162.2005.

Epand et al. **PAMAM dendrimers and model membranes: differential scanning calorimetry studies.** *International journal of pharmaceutics*,305. 154-166.2005

Essmann et al. **A smooth particle mesh Ewald method.** *The Journal of Chemical Physics*,103. 8577-8593.1995

Farkas et al. **Methodos for optimizing large molecules.** *J.chem Phys*, 4.10806-10814.1999.

Field. **A practical introduction to the simulation of molecular systems.**2 edition. Cambridge press. 344p.2007.

Fischl. (1992). **Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli.** *Ann. Intern Med.* 184-190.1992.

Fiuza. **Tratado de infectologia.** São Paulo: Editora Atheneu.2320p.1997.

Fréchet,**Dendrimers and dendritic polymers in drug delivery.** *Drug discovery today.* v10.35-43.2005.

Frisch et al. **Gaussian 03.** 2003.

Goddard III et al. **Starburst dendrimers. Part V: Molecular shape control.** *Am Chem Soc.*V111. 2339-2341.2009.

Goddard III et al. **Structures and Transport Properties of Hydrated Water-Soluble Dendrimer-Grafted.** *J. Phys. Chem.* 2759-2769.2006.

Goodman. **As Bases Farmacológicas da Terapêutica.** artmed.12 edição.2112p.2006.

Gorman et al. **Effect of repeat unit flexibility on dendrimer conformation as studied by atomistic molecular dynamics simulations.** *Polymer.*41.675-683.2000.

Guillot, B. **A reappraisal of what we have learnt during three decades of computer simulations on water.** *J. Mol. liquid.*101. 219-260.2002

Hannah et al. **Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers.** *Polymer International.*56(4).489-496.2007.

Hess, B. **P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation.** *J. Chem. Theory Comput.*4(1).116–122.2008.

Hinchliffe. **A Molecular Modeling for Beginners.**Willey.Second edition.432p.2003.

Horn, H. **Development of an improved four - site water model for biomolecular simulations: TIP4P** - *Ew. J. Chem. Phys.*120. 9665-9678.2004.

Hyperchem. **Hyperchem 7.0**. Retrieved from Hyperchem: www.hyper.com.2002

Irvine et al. **Cells a tool for membrane permeability screening**. *International Journal of Pharmaceutics*. 88. 263-267.1999.

Iseman. **Treatment of multidrug-resistant tuberculosis**. *N.Engl J. med.*11. 784-791.1993

Jorgensen et al. **Comparasion of simple potential functions for simulating liquid water**. *J Chem Physics*.79.10p.1993.

Kapur et al. **Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase B subunit in rifampicin - resistant Mycobacterium tuberculosis strains from New York City and Texas**. *J.Clin Microbiol.*32(4).1095-1994.1994.

Karatasos et al. **Association of a Weakly acidic anti-inflammatory drug (ibuprofen) with a poly (Amidoamine) Dendrimer as studied by molecular Dynamics Simulations**. *J.Phys Chem*.113(31).10984-10993.2009.

Kitchens. **Endocytosis Inhibitors Prevent Poly(amidoamine) Dendrimer Internalization and Permeability across Caco-2 Cells**. *Molecular Pharmaceutics*.5(2). 364–369.2008.

Kitchens et al. **Transepithelial and endothelial transport of poly (amidoamine) dendrimers**. *Advance drug delivery reviews*.57(15).2164-2176.2004.

Kono et al. **Transfection Activity of Polyamidoamine Dendrimers Having Hydrophobic Amino Acid Residues in the Periphery**. *Bioconjugate Chem*.34, 208-214.2005.

Kukol. **Molecular Modeling of Proteins**. Humana Press.383p.2008.

Labieniec et al. **PAMAM dendrimers – diverse biomedical applications. Facts and unresolved questions**. *Versita*.4. 434-451.2009.

Lattari et al. **Liberação controlada de isoniazida e rifampicina em conjugados com dendrímeros PAMAM**.UFRJ.2005.

Leach. **Molecular Modelling: Principles and Applications**.*Mc Gran Hill*.773p. 2001

- Lee et al. **Molecular dynamics simulations of PAMAM dendrimer-induced pore formation in DPPC bilayers with coarse-grained model.** *Journal of Physical Chemistry*.110(37).18204-18211.2006.
- Lee et al. **Coarse-Grained Molecular Dynamics Studies of the Concentration and Size Dependence of Fifth- and Seventh-Generation PAMAM Dendrimers on Pore Formation in DMPC Bilayer.** *J. Phys. Chem.*112(26). 7778–7784.2008.
- van der Spoel et al. **Gromacs: Fast, Flexible and Free.** *J.com chem* 26, 1701-1718.2005.
- Liu et al. **PAMAM dendrimer undergo pH responsive conformational changes without swelling.** *Journal of American Chemistry Society*.34. 2798-2799.2009.
- Lucia et al. **Tuberculose resistente: revisão molecular.** *REv Saúde Pública*.36(4). 525-532.2002.
- Maiti et al. **Solvent quality changes the structure of G8 PAMAM dendrimer, a disagreement with some experimental interpretations.** *J.Phys Chem*.110(51) 25628-25632.2006.
- Majoros. **Dendrimers based nanomedicine.** Pan Stanford publishing.434p.2008.
- Mayo et al. **Dreiding: A generic force field for molecular simulations.** *J.Phys Chem*.94. 8897-8909.1990.
- Minglu et al. **Evaluation of polyamidoamine PAMAM dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug.** *European journal of medicinal chemistry*.42(1) 1-6.2006.
- Ministério da Saúde. *Portal saúde.* acessado 2012, from Portal saúde: http://portal.saude.gov.br/portal/saude/profissional/visualizar_texto.cfm?idtxt=31081.2011.
- Misra A. **Inhaled drug therapy for treatment of tuberculosis.** *Tuberculosis*.91(1). 71-81.2010.
- Mitchison. **A influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.** *Am.Rev Respir. Dis.*133(3) 423-430.1986.
- Nash et al. **Rifampicin resistance in mycobacterium tuberculosis by a use of rapid , simple and specific RNA/RNS mismatch assay.** *J.Infect Dis*.533-536.1997.
- Nico et al. **Hydration Thermodynamics properties of amino acid analogues: systematic comparison of biomolecular force fields and water models.** *J.Phys Chem*.110(35).17616-17626 .2006.

Pandit. (2008). **Introdução às ciências Farmacêuticas**. Porto Alegre: artmed.336p.2006.

Peng et al. **Acurrate determination of pyridine-poly(amidoamine) dendrimer adsolute binding cosntants with the opsl-aa force field and direct integration of radial distribution functions**. *J. Phys.Chem.*109(31). 15145-15149.2005.

Prabal et al. Effect of solvent and pH on the structure of PAMAM dendrimers. *Macromolecules*.(38)3. 979-991.2005.

Prabal et al. **Structure of PAMAM Dendrimers: Generations 1 through 11**. *Macromolecules*.37. 6236-6254.2004.

Rachaneekorn et.al. **Transport of dendrimer nanocarriers through epithelial cells via the transcellular route**. *Journal of Controlled Release*.97(2). 259–267.2004.

Ramachandran et al. *Computational Chemistry and Molecular modeling*. Springer.405p.2008.

Ribeiro et al. **MKTOP**. *Braz Chem. Soc.* v19.7.1433-1435.2008.

Rieder. **Interventions for tuberculosis control and eliminations**. *International Union Against Tuberculosis and Lung Disease*. International Union Against Tuberculosis and Lung Disease.Paris France. 2009.

Roberts et al. **Molecular Dynamics of poly(l-lysine) dendrimers with naphthalene disulfonate caps**. *Macromolecules*.42(7).2775-2783.2009.

Roberts et al. **Molecular Dynamics of Variegated Polyamide Dendrimers**. *Macromolecules*.42. 2784–2794.2009.

Roberts, **Molecular modeling of polyamidoamine (PAMAM). Starbust dendrimers**. *European polymer journal*. 647-651.1999.

Rowland. **Introdução a Farmacocinética e à Farmacodinâmica** . artmed.436p.2009.

Sadekar et al. **Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery**.*Adv drug delivery review*.64(6).2012.

Sakharov et al. **Binding and retention of polycationic peptides and dendrimers in the vascular wall**. *FEBS letters*.537. 6-10.2003.

Sayed et al. **Transport mechanism of poly (amidoamine) dendrimers across caco-2 cell monolayer**. *International journal of pharmaceutics*.81. 151-157.2003

Sayed et al. **Extravasation of poly (amidoamine) (PAMAM) dendrimers across microvascular network endothelium.** *Pharmaceutical reviews*.18(11) 2001.

Spindola et al. **Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains isolated in Brazil and France.** *Mem.Inst Oswaldo Cruz*. 247-250.2001.

Spoel et al. **GROMACS Tutorial.** version 4.0.2006.

Taniguchi et al. **Rifampicin resistance and mutation of the rpoB gene in mycobacterium tuberculosis.** *FEMS, Microbiol Lett*.144(1)103-108.1996.

Tarajobi et al. **Transport of poly amidoamine dendrimers across Madim - Darby canine Kidney cells.** *International journal of Pharmaceutics*. 263-267.2001.

Telenti et al. **Detection of rifampicin resistance mutations in Mycobacterium tuberculosis.***Lancet*.341(886).647-650.1993.

Fiona et.al. **The Third industrialfluids properties simulation challenge.** *Fluid Fase Equilibria*.260(2). 153-163.2007.

Tomalia. **Dense star polymers having core, core branches, terminal groups.** terminal groups United States The Dow Chemical Corporation (Midland, MI)4507466.<http://www.freepatentsonline.com/4507466.html> 1983.

Tomalia.**Amino Amine drimers: from biomicry to drug delivery and biomedical applications.***Drug Discovery Today*. 89(6) 2001.

Rajesh Babu et al. **Dendrimers: A new carrier System for drug delivery.** *International Journal of Pharmaceutical and applied sciences* .1.2010.

Vega et al. **Relation between the melting temperature and the temperature of maximumdensity for the most common models of water.** *The Journal of chemical physics*.123. 2005.

Walter & Michael. **Simplifying the synthesis of dendrimers: accelerated approaches.** *Chem Soc Rev*.41(13).4593-4609.2012.

Williams et al. **Characterization of rifampicin resistance in pathogenic Mycobacteria.** *Antimicrob. Agents Chemother*. 38(10).2380-2386.1994.

Wiwattanapatapee et al. **Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system.** *Pharm. Res*.17(8). 991–998.2009.

Yamanda, e. a. **Alteration of ribosomes and RNA polymerase in drug-resistant clinical isolates of Mycobacterium tuberculosis.** *Antimicrob Agents.*27(6). 921-924.1985.

Yiyun, C. **Polyamidoamine dendrimers used as solubility enhancers of ketoprofen.** *European Journal of Medicinal Chemistry.*40(12). 1390-1393.2005.

Zhang et al. **RGD-modified PEG–PAMAM–DOX conjugates: In vitro and in vivo studies for glioma.** *European Journal of Pharmaceutics and Biopharmaceutics.*79(2). 232–240.2011.